An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Pexidartinib (Primary) ; Midazolam; Tolbutamide
- Indications Gastrointestinal stromal tumours; Leukaemia; Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 11 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 19 Feb 2018.